Advertisement

Influence of Cardiovascular Drugs on Platelet Aggregation

  • W. Förster
  • H.-U. Block
  • C. Giessler
  • I. Heinroth
  • P. Mentz
  • K. Pönicke
  • W. Rettkowski
  • U. Zehl

Abstract

All vasodilatory drugs reported in this chapter possess an antiaggregatory effect on platelets, some of them with a synergistic effect on prostacyclin-induced inhibition of aggregation. Thus, the question seems valid whether the antiaggregatory effect represents one part of their antianginal and antihypertensive action. Some vasodilators stimulate the biosynthesis of prostacyclin and/or other vasodilating prostaglandins. This stimulation could be linked not only to the antiaggregatory but also to the vasodilating action. The influence on prostaglandin biosynthesis, however, is not obligatory for all vasodilators, as nitroglycerin proves. Trapidil inhibits the biosynthesis and the effect of thromboxane A2, as our own experiments and those by Ohnishi et al. (7) have shown. This effect could be favorable in patients with heart infarction. Lefer et al. (5) have demonstrated a fivefold increase in thromboxane release after experimental ligation of the coronary artery in the cat. Pinane thromboxane, a thromboxane antagonist, almost completely abolished all deleterious consequences of ischemia. Whether trapidil is also able to inhibit thromboxane biosynthesis and activity under clinical conditions of heart infarction will be the topic of further investigations.

Keywords

Platelet Aggregation Aortic Ring Heart Infarction Nitroprusside Sodium Thromboxane Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frishman, W. H., Weksler, B., Christodoulu, J. P., Smithen, C., and Killin, T. 1974. Reversal of abnormal platelet aggregability and change in patients with angina pectoris following oral propranolol. Circulation 50:884–896.CrossRefGoogle Scholar
  2. 2.
    Füller, H., Hauschild, F., Modersohn, D., and Thomas, E. 1971. Pharmakologie des 5-Methyl-7-diäthylamino-s-triazolo-(1.5-a)pyrimidin (Trapymin, Rocornal(R)), einer Verbindung mit koronargefäßerweiternder Wirkung. Pharmazie 26:554–562.PubMedGoogle Scholar
  3. 3.
    Kaverina, N. V., Arefolow, V. A., Grigorieva, E. K., and Panasynk, L. V. 1976. [The influence of nonachlazine on the uptake and release of noradrenaline. J Farmakol. Toxikol. 34:420–424.Google Scholar
  4. 4.
    Kaverina, N. V., Markova, G. A., Chichkanov, G. G., Chumburidze, V. B., and Basaeva, A. J. 1975. [Nonachlasine—a new drug for the treatment of ischaemic heart disease.] Kardiologiia 15:43–48.PubMedGoogle Scholar
  5. 5.
    Lefer, A. M., Ogletree, M. L., and Smith, E. F. 1980. Role of prostanoids in acute myocardial ischemia. In: W. Foerster (ed.), Prostaglandins and Thromboxanes, pp. 15–20. VEB Gustav Fischer Verlag Jena.Google Scholar
  6. 6.
    Morcillo, E., Reid, P. R., Dubin, N., Ghodgaonkar, R., and Pitt, B. 1980. Myocardial prostaglandin E release by nitroglycerin and modification by indomethacin. Am. J. Cardiol. 45:53–57.CrossRefGoogle Scholar
  7. 7.
    Ohnishi, H., Kosuzume, H., Yamaguchi, K., Suzuki, Y., and Itho, R. 1979. Experimental studies of trapidil on thromboxane A2 (TXA2) induced aggregation of platelet, ischemic changes in heart and synthesis of TXA2. Atherosclerosis 7:407–415.Google Scholar
  8. 8.
    Parratt, J. R., and Coker, S. 1980. The significance of prostaglandin and thromboxane release in acute myocardial ischemia. In: W. Förster (ed.) Prostaglandins and Thromboxanes, pp. 21–25. VEB Gustav Fischer Verlag Jena.Google Scholar
  9. 9.
    Schüffler, J., and Frey, J. 1977. Zur Therapie des akuten Myokardinfarktes mit Rocornal. Medicamentum (Berl.) 18:11–14.Google Scholar
  10. 10.
    Weser, C., Müller, J. H. A., and Henkel, C. 1972. Zur Anwendung von Rocornal in der dringlichen Medizin. Dt. Gesundh.-Wesen 27:830–834.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • W. Förster
    • 1
  • H.-U. Block
    • 1
  • C. Giessler
    • 1
  • I. Heinroth
    • 1
  • P. Mentz
    • 1
  • K. Pönicke
    • 1
  • W. Rettkowski
    • 1
  • U. Zehl
    • 1
  1. 1.Department of Pharmacology and Toxicology, Faculty of MedicineMartin Luther University, Halle-WittenbergHalleGerman Democratic Republic

Personalised recommendations